...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Advances in clinical next-generation sequencing: target enrichment and sequencing technologies
【24h】

Advances in clinical next-generation sequencing: target enrichment and sequencing technologies

机译:临床下一代测序的进展:靶标富集和测序技术

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The huge parallel sequencing capabilities of next generation sequencing technologies have made them the tools of choice to characterize genomic aberrations for research and diagnostic purposes. For clinical applications, screening the whole genome or exome is challenging owing to the large genomic area to be sequenced, associated costs, complexity of data, and lack of known clinical significance of all genes. Consequently, routine screening involves limited markers with established clinical relevance. This process, referred to as targeted genome sequencing, requires selective enrichment of the genomic areas comprising these markers via one of several primer or probe-based enrichment strategies, followed by sequencing of the enriched genomic areas. Here, the authors review current target enrichment approaches and next generation sequencing platforms, focusing on the underlying principles, capabilities, and limitations of each technology along with validation and implementation for clinical testing.
机译:下一代测序技术的巨大并行测序功能使其成为表征研究和诊断目的基因组畸变的首选工具。对于临床应用而言,由于要测序的基因组面积大,相关的成本,数据复杂性以及所有基因缺乏已知的临床意义,因此筛选整个基因组或外显子组具有挑战性。因此,常规筛查涉及具有确定临床意义的有限标志物。该过程称为靶向基因组测序,需要通过几种基于引物或探针的富集策略之一来选择性富集包含这些标记的基因组区域,然后对富集的基因组区域进行测序。在这里,作者回顾了当前的目标富集方法和下一代测序平台,重点介绍了每种技术的基本原理,功能和局限性以及临床测试的验证和实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号